Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024
13 5월 2024 - 10:00PM
Chromocell Therapeutics Corporation (“Chromocell”, or the
“Company”), (NYSE American: CHRO), a pioneer in the development of
non-opioid pain treatment therapeutics, today announced that its
CEO Frank Knuettel, will be presenting at Alliance Global Partners
Healthcare Company Showcase on Tuesday, May 21, 2024.
The conference provides Alliance Global
Partners’ top healthcare companies with an opportunity to discuss
what they think are important industry catalysts and share some
input on where they see the industry progressing in the coming
months and years.
The showcase will consist of 20-minute ‘fireside
chat’ style presentations moderated by A.G.P.’s Jim Molloy and
Scott Henry.
Investors may attend and observe the
presentations throughout the day at the following link: A.G.P.
Healthcare Showcase Registration.
About Chromocell
Chromocell Therapeutics Corporation is a
clinical-stage biotechnology company focused on developing and
commercializing novel, non-opioid, non-addictive therapeutics to
alleviate pain and other associated medical conditions. The
Company’s initial clinical focus is to selectively target the
sodium ion-channel known as NaV1.7 for the treatment of various
types of chronic neuropathic pain and acute and chronic eye pain.
The Company’s portfolio also includes pre-clinical work on other
sodium channel receptor subtypes, and the Company intends to
explore these and other compounds for the treatment of additional
pain indications. For company updates and to learn more about
Chromocell, visit www.chromocell.com or follow us
on social media.
Forward-Looking Statements
This press release contains forward-looking
statements regarding the Company’s current expectations. These
forward-looking statements include, without limitation, references
to the Company’s expectations regarding (i) the initiation, timing,
progress and results of preclinical and clinical trials for CC8464,
CT2000 and other clinical programs, (ii) the timing, scope or
results of regulatory filings and approvals, including timing of
final FDA marketing and other regulatory approval of CC8464 and
CT2000, (iii) the Company’s ability to achieve certain accelerated
or orphan drug designations from the FDA, (iv) the Company’s
estimates regarding the potential market opportunity for CC8464 and
CT2000, (v) the Company’s plans and ability to successfully develop
and commercialize compounds, (vi) the Company’s belief that its
portfolio of therapeutics will be suitable for a multitude of eye
pain indications, (vii) the Company’s belief that the market
opportunity in under-served markets is considerable, (viii) the
Company's intent to explore certain compounds for the treatment of
pain indications, (ix) the Company's financial performance, (x) the
impact of laws and regulations, (xi) the Company's ability to
establish and maintain collaborations or obtain additional funding
and (x) the anticipated use of net proceeds from the IPO. These
statements are not guarantees of future performance and are subject
to certain risks, uncertainties and assumptions that are difficult
to predict. Factors that could cause actual results to differ
materially from those set forth in such forward-looking statements
include, but are not limited to, risks and uncertainties related to
(i) the Company expending its limited resources to pursue a
compound or indication and failing to capitalize on different
compounds or indications that may be more profitable or for which
there is a greater likelihood of success and the Company
potentially not being successful in discovering, developing and
commercializing additional compounds, (ii) the Company needing to
establish its market development capabilities to commercialize its
products with the failure to do so potentially resulting in an
inability to generate any revenue, (iii) the Company facing
significant competition and its competitors potentially achieving
regulatory approval before the Company or developing therapies that
are more advanced or effective than the Company’s, which may
adversely affect the Company’s financial condition, (iv) the
Company’s ability to obtain and maintain adequate U.S. and foreign
patent protection for its compounds, the Company facing litigation
or administrative proceedings by a third-party over its patents,
changes in U.S. or foreign patent law or interpretation thereof
diminishing the value of its patents, and the Company’s ability to
protect the confidentiality of its trade secrets, (v) third-parties
instituting patent litigation against the Company in the U.S. or a
foreign jurisdiction asserting that CC8464, CT2000 and/or
additional compounds infringe its patent rights, the outcome of
which would be uncertain and could have a material adverse effect
on the success of the Company’s business, (vi) there being no
guarantee that the results from prior clinical and preclinical
studies will be indicative of the Company’s ability to complete
studies or the results to be obtained in the current or future
studies and clinical trials and (vii) the Company’s ability to
retain key employees and scientific advisors and to attract, retain
and motivate qualified personnel. These and other risks and
uncertainties are described more fully in the section captioned
“Risk Factors” in the Company’s Registration Statement on Form S-1
(SEC File No. 333-269188). Forward-looking statements contained in
this announcement are made as of this date, and the Company
undertakes no duty to update such information except as required
under applicable law.
Chromocell Media and Investor Inquires:
LR Advisors LLC.Jason
Assad678-570-6791Jason@Chromocell.com
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024